Biomeme’s pre-aliquoted and field-friendly M1 Sample Prep® Cartridge Kit for RNA 2.0 enables you to extract purified nucleic acids from a variety of target types (e.g., viruses) and sample matrices (e.g., swabs, transport media) in minutes.
Each single-use cartridge includes a syringe and binding column tip. There’s no lab equipment, refrigeration, electricity, incubation, alcohol precipitation, or phenol chloroform extraction required. Instead, the cartridges utilize a filtration-based method in which nucleic acids selectively bind to the silica membrane inside our proprietary sample prep columns. Subsequent washes through a sequence of formulated buffers yields purified nucleic acids upon elution.
Each order includes the following:
|M1 Sample Prep® Cartridge||Cartridge containing Biomeme Lysis Buffer (BLB), Protein Wash (BPW), Wash Buffer (BWB), Drying Wash (BDW), and Elution Buffer (BEB)||96|
|Single-use 1mL Syringe||For use with M1 Sample Prep® Cartridge||96|
|Biomeme Sample Prep Column||Attaches to single-use 1mL Syringe||96|
Effortless: the extraction method is designed to be completed in 7 simple steps from sample collection thru elution.
Shelf-stable: all components are shelf-stable for 1 year when stored in a dry place, at room temperature (15-30°C / 59-86°F).
Lab-free: each cartridge comes pre- aliquoted for field-friendly transport and use, expediting DNA and RNA isolation anywhere.
Fast: complete sample prep in just a few minutes and results in 30-60 minutes when combined with a Biomeme thermocycler.
Pocket-sized: 2.65" L x 1" W x 0.7" H and weighing in at just under 13 grams keeps transportation light and cost-effective.
All-purpose: used by many industry leaders ranging from biothreat surveillance to environmental monitoring, food safety, and more.
Product Sheet: M1 Sample Prep Cartridge for RNA 2.0
Safety Data Sheet: M1 Sample Prep Cartridge for RNA 2.0 (IVD)
For Use Under an Emergency Use Authorization (EUA) Only. Rx Only | For In-Vitro Diagnostic Use.
This IVD kit is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a that meet requirements to perform high complexity tests.
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.